Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Dull

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
Vaccine|February 17, 2025
Human papillomavirus type 16 and 18 viral clearance and progression to precancer among women aged 18-25 years enrolled in the Costa Rica HPV prophylactic vaccine trial (CVT)Mónica S Sierra, Loretto J Carvajal, Peter Dull, et al.
Vaccine|December 5, 2016
Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trialMildred A Iro, Matthew D Snape, Merryn Voysey, et al.
Vaccine|May 10, 2017
Corrigendum to "Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial" [Vaccine 35 (2017) 395-402]Mildred A Iro, Matthew D Snape, Merryn Voysey, et al.
Vaccine|December 22, 2021
Towards a population-based threshold of protection for COVID-19 vaccinesDavid Goldblatt, Andrew Fiore-Gartland, Marina Johnson, et al.
JAMA|February 10, 2012
Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trialNicoletta Gossger, Matthew D Snape, Ly-Mee Yu, et al.
The American Journal of Tropical Medicine and Hygiene|August 27, 2009
Etiologies of bacterial meningitis in Bangladesh: results from a hospital-based studyEmily S Gurley, M Jahangir Hossain, Susan P Montgomery, et al.
Preventive Medicine Reports|August 14, 2023
State-of-the-Science of human papillomavirus vaccination in women with human immunodeficiency Virus: Summary of a scientific workshopAnne E Schuind, Helen Rees, John Schiller, et al.
Vaccine|August 25, 2022
Understanding the public health value and defining preferred product characteristics for therapeutic human papillomavirus (HPV) vaccines: World Health Organization consultations, October 2021-March 2022Holly J Prudden, Sharon L Achilles, Celina Schocken, et al.
Emerging Infectious Diseases|October 25, 2002
Specific, sensitive, and quantitative enzyme-linked immunosorbent assay for human immunoglobulin G antibodies to anthrax toxin protective antigenConrad P Quinn, Vera A Semenova, Cheryl M Elie, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Vaccine|February 17, 2025
Human papillomavirus type 16 and 18 viral clearance and progression to precancer among women aged 18-25 years enrolled in the Costa Rica HPV prophylactic vaccine trial (CVT)Mónica S Sierra, Loretto J Carvajal, Peter Dull, et al.
Vaccine|December 5, 2016
Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trialMildred A Iro, Matthew D Snape, Merryn Voysey, et al.
Vaccine|May 10, 2017
Corrigendum to "Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial" [Vaccine 35 (2017) 395-402]Mildred A Iro, Matthew D Snape, Merryn Voysey, et al.
Vaccine|December 22, 2021
Towards a population-based threshold of protection for COVID-19 vaccinesDavid Goldblatt, Andrew Fiore-Gartland, Marina Johnson, et al.
JAMA|February 10, 2012
Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trialNicoletta Gossger, Matthew D Snape, Ly-Mee Yu, et al.
The American Journal of Tropical Medicine and Hygiene|August 27, 2009
Etiologies of bacterial meningitis in Bangladesh: results from a hospital-based studyEmily S Gurley, M Jahangir Hossain, Susan P Montgomery, et al.
Preventive Medicine Reports|August 14, 2023
State-of-the-Science of human papillomavirus vaccination in women with human immunodeficiency Virus: Summary of a scientific workshopAnne E Schuind, Helen Rees, John Schiller, et al.
Vaccine|August 25, 2022
Understanding the public health value and defining preferred product characteristics for therapeutic human papillomavirus (HPV) vaccines: World Health Organization consultations, October 2021-March 2022Holly J Prudden, Sharon L Achilles, Celina Schocken, et al.
Emerging Infectious Diseases|October 25, 2002
Specific, sensitive, and quantitative enzyme-linked immunosorbent assay for human immunoglobulin G antibodies to anthrax toxin protective antigenConrad P Quinn, Vera A Semenova, Cheryl M Elie, et al.
Pageof 4